Literature DB >> 2017151

Mechanism of A2 adenosine receptor activation. I. Blockade of A2 adenosine receptors by photoaffinity labeling.

M J Lohse1, K N Klotz, U Schwabe.   

Abstract

It has previously been shown that covalent incorporation of the photoreactive adenosine derivative (R)-2-azido-N6-p-hydroxy-phenylisopropyladenosine [(R)-AHPIA] into the A1 adenosine receptor of intact fat cells leads to a persistent activation of this receptor, resulting in a reduction of cellular cAMP levels [Mol. Pharmacol. 30:403-409 (1986)]. In contrast, covalent incorporation of (R)-AHPIA into human platelet membranes, which contain only stimulatory A2 adenosine receptors, reduces adenylate cyclase stimulation via these receptors. This effect of (R)-AHPIA is specific for the A2 receptor and can be prevented by the adenosine receptor antagonist theophylline. Binding studies indicate that up to 90% of A2 receptors can be blocked by photoincorporation of (R)-AHPIA. However, the remaining 10-20% of A2 receptors are sufficient to mediate an adenylate cyclase stimulation of up to 50% of the control value. Similarly, the activation via these 10-20% of receptors occurs with a half-life that is only 2 times longer than that in control membranes. This indicates the presence of a receptor reserve, with respect to both the extent and the rate of adenylate cyclase stimulation. These observations require a modification of the models of receptor-adenylate cyclase coupling, which is described in the accompanying paper [Mol. Pharmacol. 39:524-530 (1991)].

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2017151

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

Review 1.  The A(2A)-adenosine receptor: a GPCR with unique features?

Authors:  J Zezula; M Freissmuth
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

2.  A1 adenosine receptors expressed in CHO-cells couple to adenylyl cyclase and to phospholipase C.

Authors:  S Freund; M Ungerer; M J Lohse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

3.  Persistent activation by and receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1 MF-2 cells and in guinea pig heart.

Authors:  J Zhang; L Belardinelli; K A Jacobson; D H Otero; S P Baker
Journal:  Mol Pharmacol       Date:  1997-09       Impact factor: 4.436

4.  Adenosine A2A receptor signaling and golf assembly show a specific requirement for the gamma7 subtype in the striatum.

Authors:  William F Schwindinger; Lauren J Murphree Mihalcik; Kathryn E Giger; Kelly S Betz; Anna Maria Stauffer; Joel Linden; Denis Herve; Janet D Robishaw
Journal:  J Biol Chem       Date:  2010-07-16       Impact factor: 5.157

5.  Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors.

Authors:  K Niiya; K A Jacobson; S K Silvia; R A Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

6.  Differential coupling of 5-HT1A receptors occupied by 5-HT or 8-OH-DPAT to adenylyl cyclase.

Authors:  A Varrault; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-10       Impact factor: 3.000

Review 7.  Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.

Authors:  K A Jacobson; P J van Galen; M Williams
Journal:  J Med Chem       Date:  1992-02-07       Impact factor: 7.446

Review 8.  Adenosine A1 and A2 receptors: structure--function relationships.

Authors:  P J van Galen; G L Stiles; G Michaels; K A Jacobson
Journal:  Med Res Rev       Date:  1992-09       Impact factor: 12.944

Review 9.  Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy.

Authors:  Nina Wolska; Marcin Rozalski
Journal:  Int J Mol Sci       Date:  2019-11-03       Impact factor: 5.923

10.  High Efficacy but Low Potency of δ-Opioid Receptor-G Protein Coupling in Brij-58-Treated, Low-Density Plasma Membrane Fragments.

Authors:  Lenka Roubalova; Miroslava Vosahlikova; Jana Brejchova; Jan Sykora; Vladimir Rudajev; Petr Svoboda
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.